Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β

Authors:

Abstract
Significance: The molecular chaperone heat-shock protein 90 (Hsp90) is a key member of the cellular proteostasis network, and as such helps to protect cells against proteotoxic stress. Cancer cells have up-regulated members of this network, including Hsp90, to promote their survival and growth. Several Hsp90 inhibitors have undergone clinical trials, but these drugs, which bind to a shared nucleotide pocket in the N-terminal domain, do not differentiate between the four Hsp90 family members [Hsp90α, Hsp90β, GRP94 (glucose-regulated protein 94 kDa), and TRAP1 (tumor necrosis receptor-associated protein 1)]. In this report, we identify a pharmacophore contained within the natural product gambogic acid that binds uniquely to a site in Hsp90β, thus identifying this compound as a prototype of a new class of isoform-specific Hsp90 inhibitors.
Funding Information
  • HHS | NIH | National Cancer Institute (Z01 SC010074-12)
  • HHS | National Institutes of Health (CA 133002)
  • Cancer Research Coordinating Committee (CRC-15-380737)
  • National Science Foundation (PHY-1427654, MCB-1214457)
  • Welch Foundation (C-1792)

This publication has 66 references indexed in Scilit: